Calliditas Therapeutics AB Depreciation Expense
Calliditas Therapeutics AB reported Depreciation Expense of SEK 48.73 million for the 12-month period ending 2023-12-31, per its 20-F filed 2024-04-24.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:DepreciationExpense · last filed 2024-04-24
| Period end | Depreciation Expense 12 month |
|---|---|
| 2023-12-31 | 48.73M SEK 20-F · filed 2024-04-24 |
| 2022-12-31 | 12.91M SEK 20-F · filed 2024-04-24 |
| 2021-12-31 | 34.43M SEK 20-F · filed 2024-04-24 |
| 2020-12-31 | 2.82M SEK 20-F · filed 2023-04-26 |
| 2019-12-31 | 1.82M SEK 20-F · filed 2022-04-27 |
| 2018-12-31 | 51.00K SEK 20-F/A · filed 2022-01-14 |